Trial Profile
A Single-arm, Open-label, Multi-center Study to Determine the Specificity of Flutemetamol (18F) Injection for Excluding the Presence of Brain Amyloid in Healthy Young Adult Subjects Aged 18 to 40
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Nov 2013
Price :
$35
*
At a glance
- Drugs Flutemetamol-F-18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors GE Healthcare
- 11 Nov 2013 New trial record